More specifically, it is approved for moderate to severe OSA in adults with obesity, with the SURMOUNT-OSA trial showing that tirzepatide directly lowered the apnea-hypopnea index
Las personas que usan Zepbound o Mounjaro, los medicamentos agonistas duales, pierden un promedio de alrededor del 20% de su peso corporal, mientras que quienes toman Ozempic o Wegovy, los frmacos agonistas simples, pierden un promedio de alrededor del 14% de su peso corporal
Doctors may prescribe it off-label to treat obesity
If you notice rapid changes in your teeth, including new sensitivity, visible white spots (early decay), or dark spots, see a dentist immediately
However, based on preclinical data and early human trial findings, glucagon receptor co-activation in the context of concurrent GLP-1R and GIPR agonism is hypothesised to: Increase energy expenditure, potentially by promoting thermogenesis Enhance hepatic fat oxidation, which may reduce liver fat content Contribute to appetite suppression through central nervous system pathways These GCGR-mediated mechanisms are largely derived from preclinical and indirect human data and require confirmation in larger trials
